Pfizer Inc. (NYSE:PFE) Shares Acquired by Tyler Stone Wealth Management

Key Points

• Tylor Stone Wealth Management increased its stake in Pfizer Inc. by 49.4%, acquiring an additional 21,984 shares to hold a total of 66,453 shares valued at $1.68 million.
• Pfizer reported an EPS of $0.78 for the last quarter, exceeding expectations and achieving 10.3% revenue growth over the previous year.
• The company announced a quarterly dividend of $0.43 per share, yielding 6.8%, with the ex-dividend date set for July 25th.

Tyler Stone Wealth Management grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 49.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 66,453 shares of the biopharmaceutical company's stock after purchasing an additional 21,984 shares during the period. Tyler Stone Wealth Management's holdings in Pfizer were worth $1,684,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of PFE. William B. Walkup & Associates Inc. grew its holdings in Pfizer by 1.2% during the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock worth $1,044,000 after acquiring an additional 454 shares during the period. Members Trust Co grew its holdings in Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after acquiring an additional 467 shares during the period. Sutton Place Investors LLC grew its holdings in Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock worth $224,000 after acquiring an additional 472 shares during the period. Bellevue Group AG grew its holdings in Pfizer by 0.3% during the fourth quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock worth $3,756,000 after acquiring an additional 485 shares during the period. Finally, MSH Capital Advisors LLC grew its holdings in Pfizer by 1.4% during the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company's stock worth $876,000 after acquiring an additional 485 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on PFE shares. UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. TD Cowen decreased their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research report on Tuesday, April 22nd. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Berenberg Bank decreased their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Finally, Redburn Atlantic decreased their target price on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Pfizer presently has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Up 0.2%

Shares of NYSE:PFE opened at $25.16 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The stock's fifty day simple moving average is $24.60 and its 200-day simple moving average is $24.45. The company has a market capitalization of $143.05 billion, a P/E ratio of 13.38, a P/E/G ratio of 0.89 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The business's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.60 earnings per share. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.